---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-041894"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-09-09T12:30:16+00:00"
generated_at: "2026-09-09T12:35:13.879969+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# bioAffinity regains Nasdaq compliance; hearing cancelled, listing continues

## Summary
- Regained compliance with Nasdaq Minimum Bid Price Rule 5550(a)(2) and Rights/Warrants Rule 5560(a) as of Sept 8, 2026.
- Previously scheduled Nasdaq Hearings Panel hearing cancelled; BIAF and BIAFW continue trading on Nasdaq Capital Market.
- As of Sept 8, 2026: 1,166,625 shares outstanding; aggregate market value ~$10.4M based on closing price.
- Staff Determination on July 30, 2026 cited bid price below $1.00 for 30 consecutive days; appeal filed Aug 6, 2026.
- CEO Maria Zannes: pleased to regain compliance, focus on CyPath Lung test and pipeline.

## SEC filing metadata
- accession: 0001493152-26-041894
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-09-09T12:30:16+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226041894/0001493152-26-041894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226041894/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-041894
- JSON: https://secwatch.observer/filing/0001493152-26-041894.json
- Plain text: https://secwatch.observer/filing/0001493152-26-041894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.